Improving Quality of Life With Nabilone During Radiotherapy Treatments for Head and Neck Cancers

Côté, Mathieu; Trudel, Mathieu; Wang, Changshu; Fortin, A.

doi:10.1177/0003489415612801

Cited by 51 publications

(84 citation statements)

References 35 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“… 147 Finally, a blinded RCT study examining nabilone in head and neck cancers determined that there was no difference in pain between intervention and placebo groups ( P =0.6048) and that nabilone did not alter the time required for progression of illness by 20% ( P =0.46). 148 …”

Section: Methodsmentioning

confidence: 99%

Therapeutic potential of medicinal marijuana: an educational primer for health care professionals

Mouhamed¹,

Vishnyakov²,

Qorri³

et al. 2018

DHPS

View full text Add to dashboard Cite

With the proposed Canadian July 2018 legalization of marijuana through the Cannabis Act, a thorough critical analysis of the current trials on the efficacy of medicinal marijuana (MM) as a treatment option is necessary. This review is particularly important for primary care physicians whose patients may be interested in using MM as an alternative therapy. In response to increased interest in MM, Health Canada released a document in 2013 for general practitioners (GPs) as an educational tool on the efficacy of MM in treating some chronic and acute conditions. Although additional studies have filled in some of the gaps since the release of the Health Canada document, conflicting and inconclusive results continue to pose a challenge for physicians. This review aims to supplement the Health Canada document by providing physicians with a critical yet concise update on the recent advancements made regarding the efficacy of MM as a potential therapeutic option. An update to the literature of 2013 is important given the upcoming changes in legislation on the use of marijuana. Also, we briefly highlight the current recommendations provided by Canadian medical colleges on the parameters that need to be considered prior to authorizing MM use, routes of administration as well as a general overview of the endocannabinoid system as it pertains to cannabis. Lastly, we outline the appropriate medical conditions for which the authorization of MM may present as a practical alternative option in improving patient outcomes as well as individual considerations of which GPs should be mindful. The purpose of this paper is to offer physicians an educational tool that provides a necessary, evidence-based analysis of the therapeutic potential of MM and to ensure physicians are making decisions on the therapeutic use of MM in good faith.

show abstract

Section: Methodsmentioning

confidence: 99%

Therapeutic potential of medicinal marijuana: an educational primer for health care professionals

Mouhamed¹,

Vishnyakov²,

Qorri³

et al. 2018

DHPS

View full text Add to dashboard Cite

show abstract

“…One clinical trial specifically studied nabilone administration in patients receiving chemotherapy for head and neck carcinomas (n = 65). Compared to the placebo group, nabilone-treated patients did not experience increased quality of life, significant weight change, decreased nausea, or improved appetite during or after chemotherapy [ 160 ]. Another clinical trial recently assessed nabilone’s effect on post-operative nausea and vomiting (PONV) following elective surgery and found no difference in PONV incidence, compared to the placebo [ 161 ].…”

Section: Exploring the Direct Effects Of Cannabinoid Drugs On Bodymentioning

confidence: 99%

Targeting the Endocannabinoid CB1 Receptor to Treat Body Weight Disorders: A Preclinical and Clinical Review of the Therapeutic Potential of Past and Present CB1 Drugs

Murphy

Foll

2020

Biomolecules

View full text Add to dashboard Cite

Obesity rates are increasing worldwide and there is a need for novel therapeutic treatment options. The endocannabinoid system has been linked to homeostatic processes, including metabolism, food intake, and the regulation of body weight. Rimonabant, an inverse agonist for the cannabinoid CB1 receptor, was effective at producing weight loss in obese subjects. However, due to adverse psychiatric side effects, rimonabant was removed from the market. More recently, we reported an inverse relationship between cannabis use and BMI, which has now been duplicated by several groups. As those results may appear contradictory, we review here preclinical and clinical studies that have studied the impact on body weight of various cannabinoid CB1 drugs. Notably, we will review the impact of CB1 inverse agonists, agonists, partial agonists, and neutral antagonists. Those findings clearly point out the cannabinoid CB1 as a potential effective target for the treatment of obesity. Recent preclinical studies suggest that ligands targeting the CB1 may retain the therapeutic potential of rimonabant without the negative side effect profile. Such approaches should be tested in clinical trials for validation.

show abstract

“…A recently published placebo-controlled study demonstrated that quality of life for patients with head-and-neck cancers undergoing radiotherapy is not improved with the use of nabilone 51 . The authors postulated that nabilone on its own is not potent enough to affect symptoms.…”

Section: Nausea and Vomitingmentioning

confidence: 99%

A User’s Guide to Cannabinoid Therapies in Oncology

Maida

Daeninck

2016

Current Oncology

View full text Add to dashboard Cite

ABSTRACT"Cannabinoid" is the collective term for a group of chemical compounds that either are derived from the Cannabis plant, are synthetic analogues, or occur endogenously. Although cannabinoids interact mostly at the level of the currently recognized cannabinoid receptors, they might have cross reactivity, such as at opioid receptors.Patients with malignant disease represent a cohort within health care that have some of the greatest unmet needs despite the availability of a plethora of guideline-driven disease-modulating treatments and pain and symptom management options. Cannabinoid therapies are varied and versatile, and can be offered as pharmaceuticals (nabilone, dronabinol, and nabiximols), dried botanical material, and edible organic oils infused with cannabis extracts. Cannabinoid therapy regimens can be creative, involving combinations of all of the aforementioned modalities. Patients with malignant disease, at all points of their disease trajectory, could be candidates for cannabinoid therapies whether as monotherapies or as adjuvants.The most studied and established roles for cannabinoid therapies include pain, chemotherapy-induced nausea and vomiting, and anorexia. Moreover, given their breadth of activity, cannabinoids could be used to concurrently optimize the management of multiple symptoms, thereby reducing overall polypharmacy. The use of cannabinoid therapies could be effective in improving quality of life and possibly modifying malignancy by virtue of direct effects and in improving compliance or adherence with disease-modulating treatments such as chemotherapy and radiation therapy.

show abstract

Improving Quality of Life With Nabilone During Radiotherapy Treatments for Head and Neck Cancers

Abstract: At the dosage used, nabilone was not potent enough to improve the patients' quality of life over placebo.

Cited by 51 publications

References 35 publications

Therapeutic potential of medicinal marijuana: an educational primer for health care professionals

Therapeutic potential of medicinal marijuana: an educational primer for health care professionals

Targeting the Endocannabinoid CB1 Receptor to Treat Body Weight Disorders: A Preclinical and Clinical Review of the Therapeutic Potential of Past and Present CB1 Drugs

A User’s Guide to Cannabinoid Therapies in Oncology

Contact Info

Product

Resources

About